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introduction: Bladder cancer (BCa) is among the most frequent cancer entities and rel-
evantly contributes to cancer-associated deaths worldwide. The multi-protein Mediator 
complex is a central regulator of the transcriptional machinery of protein-coding genes 
and has been described to be altered in several malignancies. MED1, a subunit of the tail 
module, was described to negatively modulate expression of metastasis-related genes 
and to be downregulated in melanoma and lung cancer. In contrast, MED1 hyperactivity 
was described in breast and prostate cancer, likely due its function as a hub for nuclear 
hormone receptors. So far, only little is known about the function of the Mediator com-
plex in BCa. The aim of this study was therefore to investigate the role of MED1 in BCa 
as a prognostic biomarker and a biomarker of disease progression.
Methods: The protein expression of MED1 was assessed by immunohistochemistry (IHC) 
on tissue microarrays from 224 patients: benign urothelium n = 31, non-muscle invasive 
BCa (pTis, pT1) n = 72, and muscle invasive BCa (pT2–T4) n = 121. Comprehensive 
clinicopathological information including follow-up were available. Quantification of 
MED1 protein expression was evaluated by the semiquantitative image analysis program 
Definiens.
results: MED1 expression significantly decreased during BCa progression from benign 
urothelium to advanced BCa. Muscle invasion, the crucial step in BCa progression, was 
associated with low MED1 protein expression. Accordingly, decreased MED1 expres-
sion was found in primary BCa samples with positive lymphonodal status and distant 
metastases. Furthermore, cancer-specific survival was significantly worse in the group 
of low MED1 expression.
conclusion: Our findings show that the downregulation of MED1 is associated with 
muscle invasion, metastatic spread, and shorter overall survival in BCa.
Keywords: mediator complex, mediator, bladder cancer, MeD1, immunohistochemistry
TaBle 1 | sample size (frequency) and clinicopathological data of the 
bladder cancer (Bca) cohort.
Bca Σ = 193 Benign Σ = 31
sex
 Female 43 (22.3) 11 (35.5)
 Male 150 (77.7) 20 (64.5)
age
 Mean 67 65.6
 Median 69 65
 Range 36–94 43–81
TnM
 Tis 30 (15.4) /
 T1 42 (21.8) /
 T2 42 (21.8) /
 T3 42 (21.8) /
 T4 37 (19.2) /
 N1 22 (11.4) /
 M1 4 (2.1) /
 Muscle invasion 121 (62.7) /
  Cancer-associated death 46 (23.8) /
 Relapse 34 (19.7) /
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inTrODUcTiOn
Bladder cancer (BCa) is occurring frequently with about 
180,000 new cases and 40,000 deaths per year in the European 
Union (1). It is the fifth most common entity in men in the 
Western population and the most frequent of the urinary 
tract (1, 2). To date, BCa contributes strongly to cancer-
associated deaths worldwide, whereby the crucial step in 
BCa progression is the local invasion of the M. detrusor 
vesicae and distant metastatic spread (1, 2). Due to unspecific 
clinical symptoms, diagnosis of BCa frequently occurs at the 
muscle-invasive stage, which is often accompanied by distant 
metastases leading to unfavorable outcome. To improve the 
therapeutic management for patients suffering with BCa, a 
deeper understanding of the molecular biology of this cancer 
entity is necessary. Therefore, especially, the mechanisms of 
enhanced motility leading to muscle invasion and metastatic 
spread are of great interest to achieve better outcomes in the 
future.
Tight regulation of gene expression is important for physi-
ological tissue integrity and cellular homeostasis. In cancer, this 
regulation is frequently altered. Tissue-specific expression of 
protein-coding genes by RNA polymerase II (Pol II) is therefore 
strictly controlled (3). The multi-protein Mediator complex 
(MED) is a main coactivator of transcription and globally 
regulates the Pol II (4). By building the bridge between tran-
scriptional factors and the RNA Pol II, it is a central binding 
element integrating manifold transcriptional information (4, 5). 
In humans, the Mediator complex is a protein assembly of 33 
subunits and largely conformationally dynamic through diverse 
subunit compositions (3–5). The Mediator complex consists 
of the four modules “head,” “middle,” “tail,” and “kinase,” and 
each of the MED subunits belongs to one of those modules. 
Deregulation of separate subunits has been recently linked 
to several malignancies (6, 7). There is great evidence for the 
kinase module CDK8 to function as an oncogene in colorectal 
carcinoma and its paralog CDK19 to be overexpressed during 
prostate cancer progression (8, 9). In melanoma, downregulation 
of the tail module MED1, also known as TRAP220, triggers a 
strong tumorigenic phenotype (10) and is associated with worse 
outcome in lung adenocarcinoma (11). Interestingly, loss of 
MED1 promotes the appearance of metastases of non-small-cell 
lung cancer cells by modulating metastasis-related genes (12) 
and was associated with the downregulation of tumor suppressor 
gene dapk1 (13). Moreover, MED1 serves as a hub for nuclear 
receptors such as the estrogen (ER) or androgen receptor and 
has been linked to altered hormone receptor signaling in breast 
and prostate cancer (14–17). Nevertheless, only little is known 
about the role of the Mediator complex in BCa. Since MED1 has 
been described to be associated with metastatic spread repeat-
edly (10–13), this subunit is of high interest in this tumor entity, 
in which metastases and local invasion are crucial for patient 
outcome. We therefore investigated alterations of MED1 levels 
in BCa progression by immunohistochemical staining (IHC) in a 
large patient cohort with extensive clinical annotation including 
survival data.
MaTerials anD MeThODs
immunohistochemistry (ihc)
Ethical approval for using human material in the present study 
was obtained from the Internal Review Board of the University 
Hospital of Bonn (IRB# 036/08 and #093/12). The study partici-
pants were anonymized before their specimens were included to 
the study cohort.
Protein expression in paraffin-embedded BCa tissue was 
assessed on tissue microarrays (TMAs) from patient samples pro-
vided by the University Hospital of Bonn including benign blad-
der urothelium and BCa with different stages of disease [Table 1, 
benign urothelium n = 31, non-muscle invasive BCa (NMIBC; 
pTis, pT1) n =  72, and muscle invasive BCa (MIBC; pT2–T4) 
n = 121, in total n = 224]. Immunohistochemical staining was 
conducted on TMAs using the Ventana Benchmark automated 
staining system (Ventana Medical System, Tuscon, AZ, USA) as 
described previously (7, 9, 18, 19). In brief, slides were incubated 
at room temperature with the primary antibody: anti-TRAP220/
MED1 rabbit polyclonal (dilution 1:500, ab64965, lot number: 
GR54026, Abcam). The testing of the antibody was conducted on 
breast carcinoma tissue as the positive control regarding to the 
manufacturer. Detection of the primary antibody was done with 
the ultraView Universal DAB detection kit (Ventana Medical 
System, Tuscon, AZ, USA). Finally, slides were counterstained 
with hematoxylin and bluing reagent, dehydrated, and mounted. 
IHC staining quality was validated independently by two expe-
rienced observers. Tumor samples with a lack of tissue on the 
TMAs were excluded.
Quantification of Protein expression
MED1 nuclear expression was assessed digitally using the 
semiquantitative image analysis software Definiens Tissue Studio 
2.1 (Definiens Inc., Munich, Germany) as described previously 
FigUre 1 | representative images of the MeD1 immunohistochemical staining of benign urothelium (a), non-muscle invasive bladder cancer (Bca) 
[(B), pT1], and muscle-invasive Bca [(c), pT3], 5× and 40× objective magnification. (D) Average MED1 staining intensity (mean brown chromogen intensity) 
of the BCa cohort across increasing tumor stages.
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(7, 9, 14). Slides were scanned (Panoramic Desk, 3DHistech, 
Budapest, Hungary), and the tumor tissue in each sample was 
marked manually to exclude normal and stromal areas. For the 
benign samples tumor-free urothelium was also marked manu-
ally to differentiate between benign transitional epithelium and 
stroma. These user-specified regions of interest were analyzed by 
the Definiens software, and the average nuclear staining intensity 
(corresponding to the mean brown chromogen intensity) was 
quantified as a continuous value (arbitrary units) with higher 
values indicating stronger staining.
clinical Data and statistics
Associations to available clinicopathological parameters were 
performed based on the MED1 expression intensities. After divid-
ing the BCa patients by the mean MED1 expression for all tumor 
samples into two groups, survival analyses were evaluated by 
Kaplan–Meier estimator and log-rank test. Statistical evaluation 
was performed using Student’s t-test by SPSS and Microsoft Excel.
resUlTs
expression of MeD1 in Tumor-Free 
Urothelium and Bca Tissue
To evaluate a potential implication of MED1 protein expression 
during BCa development and progression, a large TMA including 
224 BCa patient samples (Table 1) of all tumor stages of disease 
and benign urothelium was analyzed by immunohistochemistry 
(IHC) followed by computer-based semiquantitative image anal-
ysis. Mainly, MED1 protein expression showed a predominant 
nuclear localization, as the Mediator complex interacts in the 
nucleus with the transcriptional machinery. Additionally, MED1 
was localized in the cytoplasm, where the MED1 protein is synthe-
sized (Figures 1A–C). In tumor-free urothelium, the expression 
of MED1 was present in both cellular compartments, nucleus and 
cytoplasm (Figure 1A). Further, in NMIBC (NMIBC = pTis and 
pT1), the expression intensity of MED1 was similar compared to 
the benign transitional epithelium (Figure 1B, p = 0.99), whereas 
in muscle-invasive tumor stages (MIBC = T2–T4), the nuclear 
and cytoplasmic MED1 expression was significantly decreased 
compared to benign bladder tissue (Figure 1C, p = 5E−05). In 
total, the MED1 expression consistently decreased from benign 
urothelium and preinvasive carcinoma in situ lesions (pTis) to the 
advanced BCa stages T1–4 (Figure 1D). During the crucial step 
in BCa progression, the invasion into the detrusor muscle, MED1 
protein expression was significantly downregulated compared 
to NMIBC (Figure 2A, p = 2.5E−07). Interestingly, low MED1 
expression in the primary tumor was significantly associated 
with positive lymphonodal status (N1) (Figure 2B, p = 0.03) and 
showed a tendency toward the presence of distant metastases 
(M1) at the time of diagnosis (Figure 2C, p = 0.07). Patients with 
low MED1 protein expression showed an unfavorable clinical 
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outcome and decreased survival evaluated by Kaplan–Meier 
estimator and log-rank test (Figure 2D, log-rank p = 0.02).
DiscUssiOn
MED1 is part of the highly evolutionarily conserved multi-protein 
Mediator complex. Forming a bridge between transcriptional 
factors and the RNA Pol II, the Mediator complex is a central inte-
grator of the transcriptional machinery. At the beginning of the 
transcriptional process it plays an important role in assembling 
the pre-initiation complex, which is formed on nucleosome-free 
templates. Further, through diverse functional interactions with 
chromatin cofactors the Mediator complex strongly contributes 
to chromatin remodeling (3–5). Interestingly, diverse subunits, 
especially MED1, were described to contribute to these gene-spe-
cific chromatin-remodeling processes (4, 20). The comprehensive 
molecular characterization of BCas by The Cancer Genome 
Atlas Research Network showed that chromatin regulatory 
genes were more frequently mutated in BCa than in any other 
common cancer, which suggests the chromatin structure to be 
highly relevant in BCa development (21). This indicates that the 
Mediator complex could serve a promising therapeutic target in 
BCa management.
The Mediator complex as an essential regulator of Pol II is 
localized in the nucleus. The immunohistochemical staining 
pattern for MED1 on our bladder tissue cohort showed MED1 
to be preeminently nuclear but also in the cytoplasm, where 
protein-coding genes are translated (Figures 1A–C). The immu-
nohistochemical staining pattern for MED1 on our bladder tis-
sue cohort showed MED1 to be preeminently nuclear; therefore, 
we decided to assess the nuclear MED1 expression in our BCa 
cohort. Nevertheless, some subunits have additional functions 
besides their role in the Mediator complex and to evaluate a 
possible function for cytoplasmic or Mediator complex inde-
pendent MED1 in the BCa biology further investigations are 
needed (22).
By performing immunohistochemical staining for MED1 
on a large BCa cohort, we found significantly decreased MED1 
expression during BCa development and progression to muscle-
invasive and metastatic stages (Figures 1 and 2A–C). The presence 
of lymph node metastases was significantly associated with low 
MED1 expression in the primary tumor, whereas an association 
FigUre 2 | (a) MED1 expression is significantly lower in muscle-invasive bladder cancer (MIBC) compared to non-invasive pTis and T1 [non-muscle invasive 
bladder cancer (NMIBC)]. (B,c) Decreased MED1 expression is associated with positive lymphonodal status and distant metastases. N0/M0 = no lymphonodal or 
distant metastases, N1/M1 = positive lymphonodal status or distant metastases (D) The overall survival of BCa patients with low MED1 protein expression is worse 
compared to patients with high MED1 protein expression (low = <mean, high = >mean).
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cOnclUsiOn
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